Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hibma

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Scientific Reports|February 7, 2018
Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell responseJ Zhang, C Burn, K Young, et al.
Virus Research|July 7, 2009
Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cellsMerilyn H Hibma, Nicola C Real, Anna Wiles, et al.
Physical Review Letters|December 31, 2005
Controlling orbital moment and spin orientation in CoO layers by strainS I Csiszar, M W Haverkort, Z Hu, et al.
American Journal of Respiratory and Critical Care Medicine|May 16, 2020
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis InfectionJennifer E Hibma, Kendra K Radtke, Susan E Dorman, et al.
Oncogene|March 13, 1997
The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cellsO Zatsepina, J Braspenning, D Robberson, et al.
Clinical and Translational Science|April 29, 2026
Elranatamab: Mechanism of Action, Clinical, and Translational ScienceMohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, et al.
Archives of Virology|February 4, 1999
The reactivity of monoclonal antibodies against orf virus with other parapoxviruses and the identification of a 39 kDa immunodominant proteinF M Housawi, G M Roberts, J A Gilray, et al.
Clinical and Translational Science|February 27, 2024
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinomaPing Hu, Haiqing Isaac Dai, James Bourdage, et al.
Targeted Oncology|February 25, 2025
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple MyelomaMohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, et al.
Papillomavirus Research (Amsterdam, Netherlands)|December 16, 2019
IPVS Policy Statement addressing the burden of HPV disease for Indigenous peoplesBeverley Lawton, Margaret Heffernan, George Wurtak, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Scientific Reports|February 7, 2018
Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell responseJ Zhang, C Burn, K Young, et al.
Virus Research|July 7, 2009
Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cellsMerilyn H Hibma, Nicola C Real, Anna Wiles, et al.
Physical Review Letters|December 31, 2005
Controlling orbital moment and spin orientation in CoO layers by strainS I Csiszar, M W Haverkort, Z Hu, et al.
American Journal of Respiratory and Critical Care Medicine|May 16, 2020
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis InfectionJennifer E Hibma, Kendra K Radtke, Susan E Dorman, et al.
Oncogene|March 13, 1997
The human papillomavirus type 16 E7 protein is associated with the nucleolus in mammalian and yeast cellsO Zatsepina, J Braspenning, D Robberson, et al.
Clinical and Translational Science|April 29, 2026
Elranatamab: Mechanism of Action, Clinical, and Translational ScienceMohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, et al.
Archives of Virology|February 4, 1999
The reactivity of monoclonal antibodies against orf virus with other parapoxviruses and the identification of a 39 kDa immunodominant proteinF M Housawi, G M Roberts, J A Gilray, et al.
Clinical and Translational Science|February 27, 2024
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinomaPing Hu, Haiqing Isaac Dai, James Bourdage, et al.
Targeted Oncology|February 25, 2025
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple MyelomaMohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, et al.
Papillomavirus Research (Amsterdam, Netherlands)|December 16, 2019
IPVS Policy Statement addressing the burden of HPV disease for Indigenous peoplesBeverley Lawton, Margaret Heffernan, George Wurtak, et al.
Pageof 12